Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Walgreens Boots Alliance grows Q2 sales but cuts profit target
(Sharecast News) - Shares in American retail pharmacy chain Walgreens Boots Alliance rose on Thursday despite the company cutting its annual targets due to challenging conditions in the US, as sales in its second quarter came in ahead of expectations. Guidance for adjusted earnings per share now stands at between $3.20 to $3.35 for the year ending 31 August, the mid-point of which was cut from earlier guidance of $3.20 to $3.50.
The company said was due to a "challenging retail environment" in the US, an early wind-down of its sale-leaseback program for its real estate and lower earnings from pharmaceutical distributor Cencora after a recently sold further shares.
For the second quarter ended 29 February, Walgreens reported a loss of $6.85 per share, significantly higher than the $0.81 loss a year earlier, after the firm was stung by a $5.8bn after-tax non-cash impairment relating to a loss in value of its controlling stake in startup VillageMD.
Excluding this charge, EPS increased 3.4% to $1.20, helped by the first quarter of positive earnings in the US Healthcare division.
Group sales for the second quarter were 6.3% higher than last year at $37.1bn, well ahead of the $35.9bn expected by the market, with sales growth registered across all business segments. The largest division, US Retail Pharmacy, saw 4.7% sales growth to $28.9bn.
"We're encouraged by our first quarter of US Healthcare positive adjusted EBITDA and continued topline growth alongside another quarter of strong execution in pharmacy, as we look to re-energise and evolve its impact both at Walgreens and at large," said chief executive Tim Wenworth.
"As we continue to operate in a challenging retail environment, we are taking actions to focus on customer engagement and value."
Looking ahead, despite the cut to profit guidance, the retailer said it remains confident in achieving its cost-savings target of $1bn this year as it continues to lay off staff, improve efficiency and close struggling stores.
The stock was up more than 2% at $21.46 by 0946 ET.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.